Kenneth Hilty, MD
Cardiovascular Disease · Greensboro, NCNPI 1487766267
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,399 of the $51,332 with a category attached, or 86.5%. 30 manufacturers reported payments, led by Amarin Pharma, Inc. at 50.8% of the total. Reporting peaked in 2019 at $17,333 and has fallen 57.2% since, to $7,410 in 2025. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $174.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$26K
- Amgen$22K
- Novartis$589
- Johnson & Johnson$288
- Pfizer$250
- Heartflow, Inc.$230
- plus $2K from 24 others
Across 178 payments — averaging $8539.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$983K
- Amgen$434K
- Ionis Pharmaceuticals, Inc.$103K
What the payments were for
- Speaking & faculty fees$44,39986%
- Travel & lodging$1,3013%
- Food & beverage$5,61511%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 26 | $26,090 |
| Amgen | 93 | $22,247 |
| Novartis | 37 | $589 |
| Johnson & Johnson | 23 | $288 |
| Pfizer | 15 | $250 |
| Heartflow, Inc. | 8 | $230 |
| Regeneron Healthcare Solutions, Inc. | 8 | $182 |
| ZOLL Circulation Inc | 1 | $147 |
| Boehringer Ingelheim | 8 | $140 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $131 |
| AstraZeneca | 9 | $116 |
| Esperion Therapeutics, Inc. | 7 | $113 |
| Bayer | 6 | $113 |
| Novo Nordisk | 7 | $110 |
| Abiomed | 4 | $101 |
| E.r. Squibb & Sons, L.L.C. | 5 | $64 |
| Irhythm Technologies, Inc. | 4 | $52 |
| Alnylam Pharmaceuticals Inc. | 3 | $52 |
| Cvrx, Inc. | 3 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| Gilead | 2 | $29 |
| Lundbeck LLC | 2 | $28 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $23 |
| Impulse Dynamics (USA) Inc. | 1 | $20 |
| Merck | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$25,639
- Repatha$20,960
- TherOx DS2 Console$147
- Catheter$147
- Downstream Cartridge$147
- FFRct$139
How this compares
$51,332 in reported general payments places this provider in the 90th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 1,284 | $1,124,262 |
| EliquisApixaban | 510 | $444,448 |
| XareltoRivaroxaban | 139 | $136,025 |
| EntrestoSacubitril/Valsartan | 119 | $135,582 |
| Praluent PenAlirocumab | 153 | $113,931 |
| VascepaIcosapent Ethyl | 146 | $71,871 |
| NexletolBempedoic Acid | 73 | $48,614 |
| JardianceEmpagliflozin | 50 | $35,682 |
| NexlizetBempedoic Acid/Ezetimibe | 44 | $25,279 |
| FarxigaDapagliflozin Propanediol | 25 | $16,920 |
| Repatha PushtronexEvolocumab | 15 | $13,351 |
| Icosapent Ethyl | 16 | $6,847 |
| Ezetimibe | 414 | $6,631 |
| Rosuvastatin Calcium | 393 | $4,875 |
| Metoprolol Succinate | 347 | $4,873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $250 | $444,448510 claims |
| Johnson & JohnsonXarelto | $288 | $136,025139 claims |
| NovartisEntresto | $589 | $135,582119 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $113 | $73,893117 claims |
| Boehringer IngelheimJardiance | $140 | $35,68250 claims |
| AstraZenecaFarxiga | $116 | $16,92025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Greensboro
- Tiffany RandolphGreensboro$133K
- Cameron LambertGreensboro$99K
- Wesley O'NealGreensboro$85K
- Katarina NelsonGreensboro$46K
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.